Market open
Telomir Pharmaceuticals, Inc./$TELO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.
Ticker
$TELO
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
-
ISIN
US87975F1049
Website
TELO Metrics
BasicAdvanced
$74M
-
-$0.41
-
-
Price and volume
Market cap
$74M
52-week high
$5.40
52-week low
$2.27
Average daily volume
151K
Financial strength
Current ratio
0.753
Quick ratio
0.618
Total debt to equity
-57.994
Management effectiveness
Return on assets (TTM)
-391.62%
Return on equity (TTM)
-872.57%
Valuation
Price to book
-461.85
Price to tangible book (TTM)
-461.85
Price to free cash flow (TTM)
-18.801
Growth
Earnings per share change (TTM)
-39.42%
TELO News
AllArticlesVideos
Telomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market Opportunity
Accesswire·4 days ago
Telomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic Dysphonia
Accesswire·2 weeks ago
Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells
Accesswire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Telomir Pharmaceuticals, Inc. stock?
Telomir Pharmaceuticals, Inc. (TELO) has a market cap of $74M as of May 19, 2025.
What is the P/E ratio for Telomir Pharmaceuticals, Inc. stock?
The price to earnings (P/E) ratio for Telomir Pharmaceuticals, Inc. (TELO) stock is 0 as of May 19, 2025.
Does Telomir Pharmaceuticals, Inc. stock pay dividends?
No, Telomir Pharmaceuticals, Inc. (TELO) stock does not pay dividends to its shareholders as of May 19, 2025.
When is the next Telomir Pharmaceuticals, Inc. dividend payment date?
Telomir Pharmaceuticals, Inc. (TELO) stock does not pay dividends to its shareholders.
What is the beta indicator for Telomir Pharmaceuticals, Inc.?
Telomir Pharmaceuticals, Inc. (TELO) does not currently have a Beta indicator.